Similar articles

• Transformation of histological tumor type of the cervix expressed in different tumor markers in the serum.

  Aalders JG, de Bruijn HW, Oosterhuis JW, Duk JM. Aalders JG, et al. Gynecol Oncol. 1990 Jan;36(1):110-2. doi: 10.1016/0090-8258(90)90119-6. Gynecol Oncol. 1990. PMID: 2295441 No abstract available.
• Evaluation of seven different tumour markers for the establishment of tumour marker panels in gynecologic malignancies.

  Avall Lundqvist E, Nordström L, Sjövall K, Eneroth P. Avall Lundqvist E, et al. Eur J Gynaecol Oncol. 1989;10(6):395-405. Eur J Gynaecol Oncol. 1989. PMID: 2627971
• Immunohistochemical detection of CEA, CA19-9, and DF3 in esophageal carcinoma limited to the submucosal layer.

  Ikeda Y, Kuwano H, Ikebe M, Baba K, Toh Y, Adachi Y, Sugimachi K. Ikeda Y, et al. J Surg Oncol. 1994 May;56(1):7-12. doi: 10.1002/jso.2930560104. J Surg Oncol. 1994. PMID: 8176946
• Clinical use of gynaecologic tumour markers.

  Halila H, Alfthan H, Stenman UH. Halila H, et al. Ann Chir Gynaecol. 1989;78(1):65-70. Ann Chir Gynaecol. 1989. PMID: 2547331 Review.
• Recent progress in the immunological monitoring of carcinomas using monoclonal antibodies.

  Papsidero LD. Papsidero LD. Semin Surg Oncol. 1985;1(4):171-81. doi: 10.1002/ssu.2980010403. Semin Surg Oncol. 1985. PMID: 2418482 Review.